China Healthcare | Asia Pacific Weekly Rx Express 2025.07.04 July 4, 2025 01:46 PM GMT Sino Biopharma obtained approval for recombinant human coagulation factor VIIa N01: The drug is indicated for the treatment of bleeding episodes in congenital hemophilia patients aged 12 and above, with factor VII or IX inhibitors >5 Bethesda units (BU). (Company filing, July 4, 2025) Hengrui obtained approval for an additional indication for JAK1 inhibitor (ivarmacitinib): Ivarmacitinib is China's first domestically-deve ...

Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has signed a licensing agreement with FBD to collaborate on the development, production, and commercialization of the investigational drug HCB101, a SIRPα-Fc fusion protein for cancer treatment [1][2]. Group 1: Licensing Agreement Details - Fuhong Hanlin will pay up to $59 million to FBD and up to $143 million in milestone payments based on annual net sales of the licensed product in specific regions [1]. - The agreement includes royalty payments based on a one to two-digit percentage of annual net sales of the licensed product, with potential reductions under certain conditions [1]. - The agreement allows Fuhong Hanlin to terminate the contract if FBD reaches major financial terms with third parties regarding the licensed product [1]. Group 2: Product Information - HCB101 is a SIRPα-Fc fusion protein that enhances macrophage phagocytosis of tumor cells by binding with high affinity to CD47 [2]. - The HCB101 injection has shown preliminary efficacy in early clinical trials for tumor patients, including those with solid tumors, and is currently in the Ib/IIa clinical trial phase in China [2]. Group 3: Company Background - FBD, established in 2021 and based in Hong Kong, is a subsidiary of Hanchor Bio Inc., which focuses on new drug development in the field of cancer immunotherapy [3]. - As of December 31, 2024, Hanchor Bio Inc. reported total assets of approximately NT$5.42 billion, equity of about NT$2.31 billion, and total liabilities of around NT$3.11 billion, with a net loss of approximately NT$1.354 billion and no operating revenue for 2024 [3]. - The collaboration aims to leverage both companies' strengths in drug development and commercialization to enhance Fosun Pharma's product pipeline in oncology and provide more treatment options for patients [3].

Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has signed a licensing agreement with FBD to collaborate on the development, production, and commercialization of the SIRPα-Fc fusion protein (HCB101) and related drugs in specified regions and fields [1] Group 1: Licensing Agreement Details - The agreement involves Fosun Pharma's subsidiary paying up to $59 million to FBD [1] - Additionally, Fosun Pharma will pay up to $143 million in commercial milestone payments based on the annual net sales of the licensed product in Region 1 [1] Group 2: Market Considerations - The sales performance of the licensed product may be influenced by factors such as drug demand, market competition, and sales channels, indicating potential uncertainties [1]

Group 1 - The company has entered into a licensing agreement with FBD Biologics Limited, granting an exclusive license to develop, produce, commercialize, or otherwise utilize HCB101 and its derivative pharmaceutical products in specific fields and regions [1] - The licensing agreement is effective from the date of signing and will last until the expiration of the licensing product's patent rights, which is determined by the later of the following dates: (a) fifteen years from the first commercial sale of the licensed product; (b) the expiration date of the last valid claim of the patent covering the licensed product; and (c) the expiration of the market exclusivity period for the licensed product [1]